Investor Overview

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has two clinical stage oncology candidates, RX-3117 and RX-5902 (Supinoxin™), and additional compounds in preclinical development to treat multiple types of cancer.

Shareholder Letter - August 2018

Press Releases

Date Title and Summary
Toggle Summary Rexahn Pharmaceuticals to Present at the 5th NCI Pancreatic Cancer Symposium
Preliminary Safety and Efficacy Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer will be presented ROCKVILLE, Md. , Sept. 18, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc.
Toggle Summary Rexahn Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
ROCKVILLE, Md. , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that Peter D. Suzdak , Ph.D., the Company's chief executive
Toggle Summary Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin™) in combination with KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer
ROCKVILLE, Md. , Aug. 21, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that it has entered into a clinical trial collaboration agreement

Events & Presentations

Date Event Details
Summary Toggle Mar 17-20, 2013 Mar 17 - Mar 20, 2013 12:00 AM EDT 03/17/13
Summary Toggle Apr 6-10, 2013 Apr 6 - Apr 10, 2013 12:00 AM EDT 04/06/13

Title: Mechanistic study of a new 4-(3, 5-dimethoxyphenyl)-N-(7-fluoro-3-methoxyquinoxalin-2-yl)piperazine-1-carboxamide compound (RX-5902)
 [View Poster]

Summary Toggle Apr 22-25, 2013 Apr 22 - Apr 25, 2013 12:00 AM EDT 04/22/13


©2018 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy